FY2024 Earnings Estimate for Tilray Inc Issued By Roth Capital (NASDAQ:TLRY)

Tilray Inc (NASDAQ:TLRY) – Research analysts at Roth Capital cut their FY2024 earnings estimates for Tilray in a note issued to investors on Wednesday, April 10th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings of ($0.34) per share for the year, down from their prior estimate of ($0.29). The consensus estimate for Tilray’s current full-year earnings is ($0.28) per share. Roth Capital also issued estimates for Tilray’s Q4 2024 earnings at ($0.04) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.30) EPS.

Other equities research analysts have also recently issued research reports about the stock. Alliance Global Partners lifted their price target on shares of Tilray from $2.25 to $2.75 and gave the stock a “neutral” rating in a research report on Friday, April 5th. CIBC lowered their price target on shares of Tilray from $2.25 to $2.00 and set a “neutral” rating for the company in a research report on Wednesday, April 10th. Finally, Canaccord Genuity Group lowered their price target on shares of Tilray from $4.25 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, April 10th.

Tilray Trading Down 4.2 %

Shares of NASDAQ TLRY opened at $1.82 on Monday. Tilray has a 1-year low of $1.50 and a 1-year high of $3.40. The company has a market cap of $1.35 billion, a PE ratio of -4.14 and a beta of 2.36. The company has a current ratio of 1.92, a quick ratio of 0.99 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average of $1.97 and a two-hundred day moving average of $1.97.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV grew its holdings in Tilray by 10.0% during the third quarter. Mercer Global Advisors Inc. ADV now owns 28,072 shares of the company’s stock valued at $77,000 after purchasing an additional 2,550 shares during the period. Rhumbline Advisers grew its holdings in Tilray by 20.4% during the second quarter. Rhumbline Advisers now owns 15,464 shares of the company’s stock valued at $48,000 after purchasing an additional 2,623 shares during the period. CreativeOne Wealth LLC boosted its holdings in shares of Tilray by 8.0% in the third quarter. CreativeOne Wealth LLC now owns 40,591 shares of the company’s stock valued at $112,000 after buying an additional 2,994 shares during the period. State of Wyoming boosted its holdings in shares of Tilray by 17.0% in the fourth quarter. State of Wyoming now owns 24,561 shares of the company’s stock valued at $66,000 after buying an additional 3,564 shares during the period. Finally, Mariner LLC boosted its holdings in shares of Tilray by 11.1% in the fourth quarter. Mariner LLC now owns 49,469 shares of the company’s stock valued at $133,000 after buying an additional 4,945 shares during the period. Institutional investors and hedge funds own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.